Thelansis

Neuroblastoma (NB) Emerging Therapy and TPP Insights Thelansis’s “Neuroblastoma (NB) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Neuroblastoma (NB) Overview Neuroblastoma is a malignant tumor of neural crest-derived sympathetic cells, primarily affecting children under 5. It may occur sporadically or in familial cases linked to ALK or PHOX2B mutations (autosomal dominant). Prognosis is strongly influenced by MYCN amplification and chromosomal aberrations. BARD1 and LIN28B polymorphisms are associated with susceptibility. Diagnosis relies on urinary catecholamine metabolites (HVA, VMA), CT/MRI imaging, and MIBG scintigraphy for metastasis. Bone marrow biopsy is used for staging. Differential diagnoses include Wilms tum...

Neuroblastoma (NB) Emerging Therapy and TPP Insights Thelansis’s “Neuroblastoma (NB) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attribu...